Key facts
- Revel Pharmaceuticals’s last known valuation is $15.0M (Mar 2022).
- It has raised $14.7M across 3 recorded rounds; the latest was Early Stage VC ($5.8M) in Feb 2022.
- Notable investors include Gaingels, Formic Ventures, Starbloom Capital, Kizoo Technology Capital, Lifespan Extension Advocacy Foundation — 9 tracked in total.
- Revel Pharmaceuticals has filed 3 Form Ds with the SEC since 2020, most recently Mar 2022 ($5.8M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Revel Pharmaceuticals
Funding rounds
3 roundsAbout Revel Pharmaceuticals
Developer of therapeutic enzymes designed for degrading molecular damage associated with aging. The company's platform integrates enzyme discovery and engineering capabilities, encompassing design, optimization, and production of repair based catalytic treatments that clear toxic metabolites and protein modifications, enabling healthcare providers and researchers to target a range of age related diseases such as osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes with molecular level repair.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2019
- Employees
- 7
- Website
- revelpharmaceuticals.com/
- Ownership
- Privately Held (backing)
Revel Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Revel Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Revel Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.